<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="9150">Simvastatin</z:chebi>, a 3-hydroxy-3-methylglutaryl-<z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitor, is indicated for the treatment of <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> and plays an important role in both the primary and secondary prevention of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi> is a steroid analogue approved for the treatment of <z:e sem="disease" ids="C0014175" disease_type="Disease or Syndrome" abbrv="">endometriosis</z:e>, <z:e sem="disease" ids="C0016034" disease_type="Disease or Syndrome" abbrv="">fibrocystic breast disease</z:e>, and hereditary <z:hpo ids='HP_0100665'>angioedema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Despite not being licensed, <z:chebi fb="1" ids="4315">danazol</z:chebi> has been used for other off-label indications, such as <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>), <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo>, and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: We report a case of fatal <z:hpo ids='HP_0003201'>rhabdomyolysis</z:hpo> that occurred after concomitant administration of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> and <z:chebi fb="1" ids="4315">danazol</z:chebi> in a patient with <z:chebi fb="0" ids="16039">ITP</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>CASE SUMMARY: An 80-year-old white male (height, 182 cm; weight, 90 kg) presented to the emergency department of the Clinical Hospital Centre Zemun, Belgrade, Serbia, with head injuries after an accidental fall caused by <z:hpo ids='HP_0003324'>generalized weakness</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>He denied other complaints, except <z:mp ids='MP_0002899'>fatigue</z:mp>, mild pretibial <z:hpo ids='HP_0000969'>edema</z:hpo>, and progressive bilateral leg pain and cramping that began 7 days before </plain></SENT>
<SENT sid="6" pm="."><plain>At the time of presentation, he was receiving aspirin 100 mg/d, <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> 75 mg/d, <z:chebi fb="0" ids="8774">ramipril</z:chebi> 2.5 mg/d, <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> 40 mg/d, <z:chebi fb="1" ids="4315">danazol</z:chebi> 600 mg/d, <z:chebi fb="0" ids="8382">prednisone</z:chebi> 60 mg/d, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> 40 mg/d, and long-acting insulin 24 IU/d </plain></SENT>
<SENT sid="7" pm="."><plain>After the injuries were treated, he was diagnosed with collapse and nasal <z:mp ids='MP_0009275'>contusion</z:mp>, and discharged without any changes in his therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Two days after initial presentation, the patient was readmitted to the hospital due to <z:hpo ids='HP_0002018'>nausea</z:hpo>, dark urine, and <z:hpo ids='HP_0100520'>oliguria</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> clinical signs (<z:hpo ids='HP_0100520'>oliguria</z:hpo>, dark urine, <z:hpo ids='HP_0003326'>muscle pain</z:hpo>, and tenderness) and laboratory markers (<z:chebi fb="2" ids="16919">creatine</z:chebi> kinase levels approximately 100 times the upper limit of <z:mpath ids='MPATH_458'>normal</z:mpath>, along with <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo>, <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo>, and <z:hpo ids='HP_0003073'>hypoalbuminemia</z:hpo>) were consistent with severe <z:hpo ids='HP_0003201'>rhabdomyolysis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Despite intravenous hydration, forced <z:mp ids='MP_0001762'>diuresis</z:mp>, and hemodialysis, <z:hpo ids='HP_0100520'>oliguria</z:hpo> persisted and the patient died 6 days after admission </plain></SENT>
<SENT sid="11" pm="."><plain>A score of 5 on the Naranjo adverse drug reaction probability scale was consistent with a probable association of <z:hpo ids='HP_0003201'>rhabdomyolysis</z:hpo> and concomitant treatment with <z:chebi fb="0" ids="9150">simvastatin</z:chebi> and <z:chebi fb="1" ids="4315">danazol</z:chebi> in this patient </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="35664">Statin</z:chebi>-induced <z:hpo ids='HP_0003201'>rhabdomyolysis</z:hpo> must be considered whenever muscle or motor symptoms occur, especially when concomitant treatment with known inhibitors of <z:chebi fb="0" ids="35664">statin</z:chebi> metabolism is administered </plain></SENT>
<SENT sid="13" pm="."><plain>Patients must be strictly monitored and the <z:chebi fb="0" ids="35664">statin</z:chebi> should be promptly discontinued with the <z:hpo ids='HP_0003674'>onset</z:hpo> of first signs and symptoms of <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Clinicians should be aware of the potentially fatal consequences of both approved and unapproved treatments and be alert for the early detection of toxicity </plain></SENT>
</text></document>